Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 3 of 3

Publication Record


Blind men and the refractory ITP elephant.
Chaturvedi S, McCrae KR
(2016) Blood 128: 1537-8
MeSH Terms: Humans, Inosine Triphosphate, Purpura, Thrombocytopenic, Idiopathic
Added October 23, 2016
0 Communities
1 Members
0 Resources
3 MeSH Terms
Treatment of chronic immune thrombocytopenia in children with romiplostim.
Chaturvedi S, McCrae KR
(2016) Lancet 388: 4-6
MeSH Terms: Female, Humans, Male, Purpura, Thrombocytopenic, Idiopathic, Receptors, Fc, Receptors, Thrombopoietin, Recombinant Fusion Proteins, Thrombopoietin
Added April 25, 2016
0 Communities
1 Members
0 Resources
8 MeSH Terms
Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
Bussel JB, Hsieh L, Buchanan GR, Stine K, Kalpatthi R, Gnarra DJ, Ho RH, Nie K, Eisen M
(2015) Pediatr Blood Cancer 62: 208-213
MeSH Terms: Adolescent, Blood Platelets, Child, Child, Preschool, Chronic Disease, Female, Humans, Infant, Longitudinal Studies, Male, Platelet Count, Purpura, Thrombocytopenic, Idiopathic, Receptors, Fc, Receptors, Thrombopoietin, Recombinant Fusion Proteins, Thrombopoietin, Treatment Outcome
Show Abstract · Added January 21, 2015
BACKGROUND - Treatment of chronic severe pediatric ITP is not well studied. In a phase 1/2 12-16-week study, 15/17 romiplostim-treated patients achieved platelet counts ≥50 × 10 /L, and romiplostim treatment was well tolerated. In a subsequent open-label extension (≤109 weeks), 20/22 patients received romiplostim; all achieved platelet counts >50 × 10 /L. Twelve patients continued in a second extension (≤127 weeks). Longitudinal data from start of romiplostim treatment through the two extensions were evaluated to investigate the safety and efficacy of long-term romiplostim treatment in chronic severe pediatric ITP.
PROCEDURE - Patients received weekly subcutaneous romiplostim, adjusted by 1 µg/kg/week to maintain platelet counts (50-200 × 10 /L, maximum dose 10 µg/kg). Bone marrow examinations were not required.
RESULTS - At baseline, patients were median age 10.0 years; median ITP duration 2.4 years; median platelet count 13 × 10 /L; 73% were male; and 36% had prior splenectomy. Median romiplostim treatment duration was 167 weeks (Q1, Q3: 78,227 weeks), and median average weekly dose was 5.4 µg/kg (Q1, Q3: 4.3, 8.0 µg/kg). Seven patients discontinued treatment: four withdrew consent, two were noncompliant, and one received alternative therapy. None withdrew because of adverse events (AEs). After the first 12 weeks, median platelet counts remained >50 × 10 /L. Eight (36.4%) patients received rescue medication, and 14 (63.6%) used concurrent ITP therapy. Seven patients (31.8%) reported serious AEs, and two (9.1%) reported life-threatening AEs (both thrombocytopenia); there were no serious AEs attributed to treatment and no fatalities.
CONCLUSIONS - Long-term romiplostim treatment in this small cohort increased and maintained platelet counts for over 4 years in children with ITP with good tolerability and without significant toxicity. Pediatr Blood Cancer 2015;62:208-213. © 2014. The Authors. Pediatr Blood & Cancer published by Wiley Periodicals, Inc.
© 2014 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals, Inc.
0 Communities
1 Members
0 Resources
17 MeSH Terms